ORION CORP.B UNSP.ADR 1/2 (OFK0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ORION CORP.B UNSP.ADR 1/2 (OFK0) has a cash flow conversion efficiency ratio of 0.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€37.00 Million ≈ $43.26 Million USD) by net assets (€1.12 Billion ≈ $1.31 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OFK0 equity to assets ratio to measure how much of total assets are equity-financed.
ORION CORP.B UNSP.ADR 1/2 - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how ORION CORP.B UNSP.ADR 1/2's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of ORION CORP.B UNSP.ADR 1/2 to evaluate the quality of earnings relative to operating cash generation.
ORION CORP.B UNSP.ADR 1/2 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ORION CORP.B UNSP.ADR 1/2 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Argan Inc
NYSE:AGX
|
0.239x |
|
SAINSBURY -J.- ADR/4 NEW
F:SUY
|
N/A |
|
SPIE SA
PA:SPIE
|
0.362x |
|
CITIC Metal Co. Ltd. A
SHG:601061
|
N/A |
|
GETLINK ADR EO-40
F:TNU
|
N/A |
|
Canadian Utilities Limited
TO:CU
|
0.069x |
|
SpareBank 1 Sør-Norge ASA
OL:SB1NO
|
-0.091x |
|
Abivax SA
PA:ABVX
|
-0.157x |
Annual Cash Flow Conversion Efficiency for ORION CORP.B UNSP.ADR 1/2 (2022–2025)
The table below shows the annual cash flow conversion efficiency of ORION CORP.B UNSP.ADR 1/2 from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see ORION CORP.B UNSP.ADR 1/2 (OFK0) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.28 Billion ≈ $1.50 Billion |
€316.80 Million ≈ $370.37 Million |
0.247x | -15.52% |
| 2024-12-31 | €1.00 Billion ≈ $1.17 Billion |
€293.40 Million ≈ $343.02 Million |
0.292x | +118.37% |
| 2023-12-31 | €890.10 Million ≈ $1.04 Billion |
€119.00 Million ≈ $139.12 Million |
0.134x | -72.05% |
| 2022-12-31 | €908.10 Million ≈ $1.06 Billion |
€434.40 Million ≈ $507.86 Million |
0.478x | -- |
About ORION CORP.B UNSP.ADR 1/2
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more